Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 177Neoplasm Metastasis 142Neoplasms 136Leukemia, Myeloid, Acute 128Colorectal Neoplasms 126Breast Neoplasms 115Ovarian Neoplasms 89Melanoma 88Prostatic Neoplasms 86Recurrence 84Multiple Myeloma 81Pancreatic Neoplasms 74Squamous Cell Carcinoma of Head and Neck 72Glioblastoma 72Lung Neoplasms 70Lymphoma, Non-Hodgkin 63Myelodysplastic Syndromes 60Triple Negative Breast Neoplasms 57Glioma 53Stomach Neoplasms 52Precursor Cell Lymphoblastic Leukemia-Lymphoma 49Endometrial Neoplasms 48Carcinoma, Renal Cell 47Small Cell Lung Carcinoma 46Lymphoma, Large B-Cell, Diffuse 44Brain Neoplasms 43Carcinoma, Hepatocellular 41Sarcoma 39Lymphoma, B-Cell 39Advanced Solid Tumors 39

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Squamous NSCLC × 90 days × Clear all
NCT07073183 2026-05-29

Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)

CureVac

Phase 1 Withdrawn
Thoracic

Squamous NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡